Aprea Therapeutics, Inc. (APRE) Stock Analysis & Investment Frameworks
Aprea Therapeutics, Inc. (APRE) stock analysis on Invetso. Review Aprea Therapeutics, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Aprea Therapeutics, Inc. Company Overview
- Exchange: NASDAQ Global Select
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Aprea Therapeutics, Inc. Key Financial Metrics
- Market Cap: $6.36M
- Revenue: $N/A
- ROE: -44.26%
- ROIC: -43.86%
- Dividend Yield: N/A
About Aprea Therapeutics, Inc.
Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on modulating DNA damage response pathways. The company's primary drug candidate, ATRN-119, is an oral ATR inhibitor currently undergoing Phase 1/2a clinical trials for patients with advanced solid tumors. Beyond this lead compound, Aprea's developmental pipeline includes ATRN-Backup, which is also an ATR inhibitor; ATRN-W1051, being explored for its anti-tumor effects; and ATRN-DDRi. Aprea Therapeutics, Inc. is headquartered in Boston, Massachusetts.
Aprea Therapeutics, Inc. Investment Frameworks
Invetso analyzes Aprea Therapeutics, Inc. (APRE) across the following frameworks:
- Aprea Therapeutics, Inc. 10Y Growth Potential
- Aprea Therapeutics, Inc. Scenario Analysis
- Aprea Therapeutics, Inc. Risks & Opportunities
- Aprea Therapeutics, Inc. Economic Moat
- Aprea Therapeutics, Inc. Business Model
- Aprea Therapeutics, Inc. Management
- Aprea Therapeutics, Inc. SWOT Analysis
- Aprea Therapeutics, Inc. Porter's 5 Forces
- Aprea Therapeutics, Inc. PESTLE Analysis
- Aprea Therapeutics, Inc. ESG Analysis